LUYE PHARMA (02186) announced that certain subsidiaries of the group have signed a cooperation agreement with Jiangsu Enhua and Xin Pharmaceutical Marketing Co., Ltd. (Enhua), a subsidiary of Jiangsu Enhua Pharmaceutical Co., Ltd., granting Enhua exclusive commercialization rights for three long-acting antipsychotic injectable products in Mainland China. The three products include Rui Ke Tuo (Risperidone Extended-Release Microspheres for Injection (II)), Rui Bai Lai (Paliperidone Palmitate Injection (II)), and Mei Bi Rui (Paliperidone Palmitate Injection), all indicated for the treatment of schizophrenia.
Under the agreement, Enhua will be responsible for the exclusive distribution and commercialization of these products in Mainland China, while the group retains ownership of the assets, regulatory approvals, and all intellectual property rights, as well as responsibility for production and supply. The agreement is valid for ten years. Upon signing, Enhua will make a one-time, non-refundable payment of $20 million in licensing fees to the group.
This collaboration marks a strategic partnership between two leading players in China’s central nervous system (CNS) sector, aiming to deepen market penetration in schizophrenia treatment and provide patients with more comprehensive therapeutic options. Schizophrenia is a chronic, highly relapsing, and disabling disorder. Treatment interruptions or self-reduced medication often lead to relapse and refractory schizophrenia, posing a major challenge in disease management. Long-acting injectable antipsychotics significantly improve patient adherence compared to oral formulations, serving as a critical strategy for relapse prevention.
In China, approximately 8 million people suffer from schizophrenia, with community healthcare institutions being the primary treatment centers during the consolidation and maintenance phases. The three products were independently developed based on the group’s long-acting and sustained-release technology platform. Rui Ke Tuo, with risperidone as its active ingredient, is China’s first domestically innovated second-generation long-acting injectable antipsychotic. Both Rui Bai Lai and Mei Bi Rui contain paliperidone palmitate, with Rui Bai Lai being the world’s first and only monthly paliperidone palmitate injection requiring just one dose in the first month.
Enhua is a leading CNS-focused company in China, dedicated to building integrated solutions for mental and neurological disorders and establishing a comprehensive CNS diagnosis-treatment ecosystem. With a broad product portfolio and a specialized sales team of over 2,000 professionals, Enhua has built a nationwide commercialization network covering tens of thousands of hospitals, mental health centers, primary care facilities, private hospitals, online pharmacies, and retail chains, forming a multi-channel marketing advantage.
The board of LUYE PHARMA believes that the three long-acting injectables form a differentiated product portfolio, addressing the full course of schizophrenia treatment with significant clinical value. CNS is one of the group’s core strategic areas, supported by China’s most competitive CNS product matrix and platform capabilities. Through strategic collaborations, the group aims to accelerate the commercialization of its pipeline and address unmet clinical needs while focusing on innovation and global market expansion.
This partnership with Enhua will deepen CNS market penetration, particularly in primary healthcare centers, helping more patients access standardized treatment and alleviating disease burdens.